Production (Stage)
Aura Biosciences, Inc.
AURA
$5.89
-$0.05-0.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.34% | 15.46% | 10.83% | 6.68% | 7.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.05% | 13.09% | 19.62% | 23.11% | 31.28% |
| Operating Income | -17.05% | -13.09% | -19.62% | -23.11% | -31.28% |
| Income Before Tax | -20.58% | -13.81% | -17.16% | -18.00% | -23.77% |
| Income Tax Expenses | -53.55% | -17.52% | -- | -- | -- |
| Earnings from Continuing Operations | -20.40% | -13.76% | -17.48% | -18.26% | -24.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.40% | -13.76% | -17.48% | -18.26% | -24.06% |
| EBIT | -17.05% | -13.09% | -19.62% | -23.11% | -31.28% |
| EBITDA | -17.37% | -13.38% | -20.00% | -23.46% | -31.83% |
| EPS Basic | -2.01% | 9.15% | 11.27% | 10.81% | 6.10% |
| Normalized Basic EPS | -1.87% | 9.34% | 10.82% | 10.32% | 5.59% |
| EPS Diluted | -2.01% | 9.15% | 11.27% | 10.81% | 6.10% |
| Normalized Diluted EPS | -1.87% | 9.34% | 10.82% | 10.32% | 5.59% |
| Average Basic Shares Outstanding | 17.12% | 25.32% | 32.56% | 32.80% | 32.59% |
| Average Diluted Shares Outstanding | 17.12% | 25.32% | 32.56% | 32.80% | 32.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |